Akobeng Anthony A, Sandborn William J, Bickston Stephen J, Chande Nilesh, Shackelton Lisa M, Nelson Sigrid, Feagan Brian G
*Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom; †Robarts Clinical Trials, Inc., San Diego, California; ‡Division of Gastroenterology, University of California San Diego, La Jolla, California; §Center for Inflammatory Bowel Diseases, Virginia Commonwealth University Health System, Richmond, Virginia; ‖Division of Gastroenterology, Department of Medicine, The University of Western Ontario, London, ON, Canada; ¶Robarts Clinical Trials Inc., Robarts Research Institute, The University of Western Ontario, London, ON, Canada and **Departments of Medicine and Epidemiology and Biostatistics, The University of Western Ontario, London, ON, Canada.
Inflamm Bowel Dis. 2014 Nov;20(11):2132-41. doi: 10.1097/MIB.0000000000000218.
In 1998, the U.S. Food and Drug Administration granted regulatory approval to the first tumor necrosis factor-α antagonist, infliximab, for the treatment of moderately to severely active Crohn's disease. As of 2013, there were 3 additional tumor necrosis factor-α antagonists commercially available for the treatment of inflammatory bowel disease in the United States: adalimumab, certolizumab pegol, and golimumab. Despite a vast literature describing both clinical trial and clinical practice experience with these agents, there remain important questions regarding the efficacy and safety of tumor necrosis factor-α antagonists for the treatment of inflammatory bowel disease. These questions and the best available evidence to answer them were discussed during a Cochrane Collaboration session held at the 2013 Digestive Diseases Week annual meeting. This article reviews the data from that session.
1998年，美国食品药品监督管理局批准了首个肿瘤坏死因子-α拮抗剂英夫利昔单抗用于治疗中度至重度活动性克罗恩病。截至2013年，美国还有另外3种肿瘤坏死因子-α拮抗剂可用于治疗炎症性肠病：阿达木单抗、赛妥珠单抗聚乙二醇化修饰物和戈利木单抗。尽管有大量文献描述了这些药物的临床试验和临床实践经验，但关于肿瘤坏死因子-α拮抗剂治疗炎症性肠病的疗效和安全性仍存在重要问题。在2013年消化系统疾病周年会上举行的一次Cochrane协作会议期间，对这些问题以及解答这些问题的现有最佳证据进行了讨论。本文回顾了该会议的数据。
